ISS Recommends Anavex's Full Slate in Proxy Fight With PVG
AVXL sits 16% above its 52-week low of $2.255.
Summary
Proxy advisory firm ISS recommends Anavex stockholders vote FOR all six company director nominees, dealing a blow to activist PVG's board takeover bid ahead of the September 24 annual meeting.
Key Events · Corporate Governance and Compliance · AVXL
-
ISS Backs Anavex's Full Slate
Institutional Shareholder Services recommended stockholders vote FOR all six Anavex director nominees on the WHITE proxy card, stating the dissident 'has not made a compelling case for change.'
-
ISS Rejects PVG's Case
ISS noted PVG 'has not presented a detailed go-forward plan' despite seeking a majority board position, and that PVG's slate is concentrated in investment management and equity research rather than drug development expertise.
-
Board Refreshment Validated
ISS highlighted that half the board has been refreshed since the beginning of 2026, with new members bringing drug development, early-stage company, and FDA approval process experience.
-
Annual Meeting Set for September 24
Stockholders of record as of July 31, 2026, will vote at the September 24, 2026 annual meeting, where the proxy contest with PVG will be decided.
Analysis · AVXL · Life Sciences
Institutional Shareholder Services, the most influential proxy advisory firm, has recommended that Anavex stockholders vote FOR all six of the company's director nominees on the WHITE proxy card. ISS concluded that activist PVG Asset Management 'has not made a compelling case for change' and lacks a detailed go-forward plan. This is a significant development in the September 24 boardroom showdown — ISS recommendations typically sway a meaningful bloc of institutional votes, and this endorsement directly undercuts PVG's campaign to replace the entire board. The recommendation also validates the board's recent actions, including the removal of the former CEO and the refreshment of half the board since early 2026.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 29.9% of the 1591 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.24%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AVXL was trading at $2.61 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $242.9M. The 52-week trading range was $2.26 to $10.38. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.